Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy

Lakshmi Pendyala, Gary Schwartz, Patrick Smith, Joseph Zdanowicz, Michael Murphy, Frederick Hausheer

Research output: Contribution to journalArticle

Abstract

Background: BNP7787 (disodium 2,2′-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatinand paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on the total concentrations (oxidized plus free) of cysteine, homocysteine and GSH in plasma, free and total GSH in WBC and rate of urinary excretion of cysteine were studied. The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m2) treatment which followed paclitaxel (175 mg/m2) and BNP7787 (8.2 to 27.6 g/m2). Method: Plasma thiols were measured by HPLC with fluorescence detection and platinum was measured by atomic absorption spectrophotometry. Results: BNP7787 administration produced a significant depletion of all plasma thiols in all the patients studied. Differences were noted in the kinetics of BNP7787-induced depletion of cysteine and other thiols. A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion. The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P

Original languageEnglish (US)
Pages (from-to)376-384
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume51
Issue number5
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Paclitaxel
Sulfhydryl Compounds
Disulfides
Cisplatin
Modulation
Plasmas
Cysteine
Homocysteine
Therapeutics
Platinum
Atomic Spectrophotometry
Clinical Trials, Phase I
Pharmacokinetics
2,2'-dithiodiethanesulfonic acid
TP protocol
Spectrophotometry
Half-Life
Toxicity
Fluorescence
High Pressure Liquid Chromatography

Keywords

  • BNP7787
  • Cysteine Homocysteine
  • Disulfides
  • Glutathione
  • Thiols

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Pendyala, L., Schwartz, G., Smith, P., Zdanowicz, J., Murphy, M., & Hausheer, F. (2003). Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemotherapy and Pharmacology, 51(5), 376-384.

Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. / Pendyala, Lakshmi; Schwartz, Gary; Smith, Patrick; Zdanowicz, Joseph; Murphy, Michael; Hausheer, Frederick.

In: Cancer Chemotherapy and Pharmacology, Vol. 51, No. 5, 01.05.2003, p. 376-384.

Research output: Contribution to journalArticle

Pendyala, L, Schwartz, G, Smith, P, Zdanowicz, J, Murphy, M & Hausheer, F 2003, 'Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy', Cancer Chemotherapy and Pharmacology, vol. 51, no. 5, pp. 376-384.
Pendyala, Lakshmi ; Schwartz, Gary ; Smith, Patrick ; Zdanowicz, Joseph ; Murphy, Michael ; Hausheer, Frederick. / Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. In: Cancer Chemotherapy and Pharmacology. 2003 ; Vol. 51, No. 5. pp. 376-384.
@article{16995c5d60764266a3c267b57b26f33b,
title = "Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy",
abstract = "Background: BNP7787 (disodium 2,2′-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatinand paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on the total concentrations (oxidized plus free) of cysteine, homocysteine and GSH in plasma, free and total GSH in WBC and rate of urinary excretion of cysteine were studied. The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m2) treatment which followed paclitaxel (175 mg/m2) and BNP7787 (8.2 to 27.6 g/m2). Method: Plasma thiols were measured by HPLC with fluorescence detection and platinum was measured by atomic absorption spectrophotometry. Results: BNP7787 administration produced a significant depletion of all plasma thiols in all the patients studied. Differences were noted in the kinetics of BNP7787-induced depletion of cysteine and other thiols. A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion. The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P",
keywords = "BNP7787, Cysteine Homocysteine, Disulfides, Glutathione, Thiols",
author = "Lakshmi Pendyala and Gary Schwartz and Patrick Smith and Joseph Zdanowicz and Michael Murphy and Frederick Hausheer",
year = "2003",
month = "5",
day = "1",
language = "English (US)",
volume = "51",
pages = "376--384",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy

AU - Pendyala, Lakshmi

AU - Schwartz, Gary

AU - Smith, Patrick

AU - Zdanowicz, Joseph

AU - Murphy, Michael

AU - Hausheer, Frederick

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: BNP7787 (disodium 2,2′-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatinand paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on the total concentrations (oxidized plus free) of cysteine, homocysteine and GSH in plasma, free and total GSH in WBC and rate of urinary excretion of cysteine were studied. The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m2) treatment which followed paclitaxel (175 mg/m2) and BNP7787 (8.2 to 27.6 g/m2). Method: Plasma thiols were measured by HPLC with fluorescence detection and platinum was measured by atomic absorption spectrophotometry. Results: BNP7787 administration produced a significant depletion of all plasma thiols in all the patients studied. Differences were noted in the kinetics of BNP7787-induced depletion of cysteine and other thiols. A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion. The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P

AB - Background: BNP7787 (disodium 2,2′-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatinand paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on the total concentrations (oxidized plus free) of cysteine, homocysteine and GSH in plasma, free and total GSH in WBC and rate of urinary excretion of cysteine were studied. The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m2) treatment which followed paclitaxel (175 mg/m2) and BNP7787 (8.2 to 27.6 g/m2). Method: Plasma thiols were measured by HPLC with fluorescence detection and platinum was measured by atomic absorption spectrophotometry. Results: BNP7787 administration produced a significant depletion of all plasma thiols in all the patients studied. Differences were noted in the kinetics of BNP7787-induced depletion of cysteine and other thiols. A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion. The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P

KW - BNP7787

KW - Cysteine Homocysteine

KW - Disulfides

KW - Glutathione

KW - Thiols

UR - http://www.scopus.com/inward/record.url?scp=0038695006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038695006&partnerID=8YFLogxK

M3 - Article

C2 - 12682786

AN - SCOPUS:0038695006

VL - 51

SP - 376

EP - 384

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -